Serono Rebif Reformulation Could Boost Tolerability; Firm Submits sBLA
This article was originally published in Pharmaceutical Approvals Monthly
Serono expects approval of a new formulation of its relapsing multiple sclerosis therapy Rebif in 2007, the firm announced April 4.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class